HER2 binding localizes a TLR7/8 agonist to the tumor, activating dendritic/APCs to drive cytokines and antigen presentation, which primes cytotoxic T cells that kill HER2+ tumor cells; Fc-mediated phagocytosis/ADCC may also contribute.